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Background & Aims: Virus-specific T cell dysfunction is a common feature of HBV-related hepatocellular carcinoma (HBV-
HCC). Conventional T (ConT) cells can be redirected towards viral antigens in HBV-HCC when they express an HBV-specific
receptor; however, their efficacy can be impaired by liver-specific physical and metabolic features. Mucosal-associated
invariant T (MAIT) cells are the most abundant innate-like T cells in the liver and can elicit potent intrahepatic effector
functions. Here, we engineered ConT and MAIT cells to kill HBV expressing hepatoma cells and compared their functional
properties.
Methods: Donor-matched ConT and MAIT cells were engineered to express an HBV-specific T cell receptor (TCR). Cytotoxicity
and hepatocyte homing potential were investigated using flow cytometry, real-time killing assays, and confocal microscopy in
2D and 3D HBV-HCC cell models. Major histocompatibility complex (MHC) class I-related molecule (MR1)-dependent and
MR1-independent activation was evaluated in an Escherichia coli THP-1 cell model and by IL-12/IL-18 stimulation,
respectively.
Results: HBV TCR-MAIT cells demonstrated polyfunctional properties (CD107a, interferon [IFN] c, tumour necrosis factor
[TNF], and IL-17A) with strong HBV target sensitivity and liver-homing chemokine receptor expression when compared with
HBV TCR-ConT cells. TCR-mediated lysis of hepatoma cells was comparable between the cell types and augmented in the
presence of inflammation. Coculturing with HBV+ target cells in a 3D microdevice mimicking aspects of the liver microen-
vironment demonstrated that TCR-MAIT cells migrate readily towards hepatoma targets. Expression of an ectopic TCR did not
affect the ability of the MAIT cells to be activated via MR1-presented bacterial antigens or IL-12/IL-18 stimulation.
Conclusions: HBV TCR-MAIT cells demonstrate anti-HBV functions without losing their endogenous antimicrobial mecha-
nisms or hepatotropic features. Our results support future exploitations of MAIT cells for liver-directed immunotherapies.
Lay summary: Chronic HBV infection is a leading cause of liver cancer. T cell receptor (TCR)-engineered T cells are patients’
immune cells that have been modified to recognise virus-infected and/or cancer cells. Herein, we evaluated whether mucosal-
associated invariant T cells, a large population of unconventional T cells in the liver, could recognise and kill HBV infected
hepatocytes when engineered with an HBV-specific TCR. We show that their effector functions may exceed those of con-
ventional T cells currently used in the clinic, including antimicrobial properties and chemokine receptor profiles better suited
for targeting liver tumours.
© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Hepatocellular carcinoma (HCC) is the most common form of
liver cancer, and its development is associated with chronic HBV
infection.1 Many patients with HCC do not present with symp-
toms until the disease has advanced and spread, resulting in late-Keywords: HCC; HBV; Adoptive cell transfer; MAIT cells; TCR-T cells.
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advanced HCC do not typically meet the criteria for surgical and
locoregional interventions,3 and systemic therapies such as im-
mune checkpoint inhibitors have demonstrated success in only a
minority of patients.4,5 Given that reversal of T cell exhaustion
alone may not be sufficient to restore host antitumour immunity,
adoptive T cell transfer is a promising approach to address this
unmet clinical need.
Reprogramming T cells to express T cell receptors (TCRs) with
pre-defined specificities has demonstrated success as a cancer
treatment,6 and its application to infectious diseases is
Research articleemerging.7,8 As a DNA virus, HBV possesses chromosomal inte-
grative capacity in infected hepatocytes resulting in the produc-
tion of HBV-human chimeric proteins.9,10 Although this can occur
in normal and transformed hepatocytes, the presence of integra-
tion events in >90% of HBV-HCC makes viral antigens attractive
tumour-associated targets.11 Chimeric antigen receptor (CAR)- and
TCR-T cells targeting HBV antigens have shown antiviral and anti-
HCC functionality in vitro12,13 and in murine models of HBV
infection.14–16 Furthermore, clinical trials investigating their po-
tential under different HBV-associated pathogenic states are
ongoing, with preliminary data indicating clinical benefit.11,16,17
Despite these promising results, cell therapies targeting solid
tumours such as HCC are limited by inefficient tumour infiltra-
tion and impaired activation within the local immunosuppres-
sive milieu.18 Adoptive T cell transfer typically involves systemic
infusion, and cross-talk between tumour targets and adoptively
transferred cells is crucial to ensure efficient recruitment to the
appropriate site.19 The trafficking of T cells from the blood to the
liver relies on chemokine and cytokine receptor signalling, as
well as the upregulation of adhesion molecules and integrins.18 It
has been described that further engineering of T cells with
tumour-specific chemokine receptors can augment their trans-
migration and antitumoural activity in vivo.20 However, the
introduction of additional transgenes poses a challenge to the
manufacturing process as well as the safety of the therapy.
Mucosal-associated invariant T (MAIT) cells are naturally
enriched in the liver and represent a critical innate-like T cell
subset.21,22 They express a diverse chemokine receptor profile
associated with their rapid extravasation and tissue infiltrating
properties in response to infection and inflammation.23,24 Unlike
conventional T (ConT) cells, which recognise antigens presented
by major histocompatibility complex (MHC) class I molecules
through highly variable TCRab receptors, MAIT cells are MHC
class I-related molecule (MR1) restricted and utilise a semi-
invariant Va7.2-Ja33/Ja20/Ja12 TCR with a limited set of b
chain diversity. The MAIT cell TCR recognises riboflavin biosyn-
thesis pathway metabolites, earning them a reputation as sen-
tinels of microbial infections.25 However, cancer metabolite
recognition by MR1-restricted T cells has also been demon-
strated,26 indicating a role for MR1-dependent host tumour
surveillance. TCR-mediated MAIT cell activation results in rapid
degranulation and the release of perforin and granzymes, which
effectively lyse target cells.27,28 The TCR-activated MAIT cell
cytokine profile is a combined Th1/Th17-like phenotype
involving interferon (IFN) c, tumour necrosis factor (TNF), IL-2,
IL-22, and IL-17A.29 Furthermore, MAIT cells can be activated
independently of their TCR; IL-12 and IL-18 can elicit IFNc pro-
duction in MAIT cells, and IL-15 can induce innate-like cytotoxic
effector functions in liver MAIT cells.30
Unlike other human T cell types, MAIT cell potential for liver-
targeted immunotherapy is largely unexplored.31,32 Here, we
employ a recently established protocol33 to investigate TCR-
redirected MAIT cells in the context of HBV using a preclinical
HCC cell model. Our findings are relevant for the application of
TCR-redirected MAIT cells for immunotherapy of liver diseases.Materials and methods
Human samples
For TCR engineering experiments, healthy blood donors were
recruited at the Blood Transfusion Clinic at Karolinska University
Hospital in Huddinge, Sweden. All donors provided writtenJHEP Reports 2021informed consent under the Declaration of Helsinki and
following approval by the Regional Ethics Review Board in
Stockholm Dnr 2007/115-31/1. Peripheral blood mononuclear
cells (PBMCs) were subsequently isolated by density centrifu-
gation on Ficoll-Paque (Cytiva).
Donor-matched ConT and MAIT cell expansions
Following isolation from buffy coats, PBMCs were either frozen
in 90% FBS + 10% DMSO or underwent MAIT cell expansion as
previously described.33 On Day 12/14 of the MAIT cell expansion,
paired donor PBMCs were thawed and cultured in AIM-V
(Thermo Fisher) + 2% AB serum and activated for 7 days in the
presence of 50 ng/ml anti-CD3 (eBioscience) and 600 IU/ml IL-2
(Miltenyi) to generate ConT cells as previously reported.17 On Day
7, the concentration of IL-2 was increased to 1,000 IU/ml. All cells
underwent TCR redirection by electroporation the following day.
Cytokine functional assays with HBV antigen+ target cells
Human leukocyte antigen (HLA)-A2+ T2 cells (2×105 cells/well)
were pulsed in a round-bottomed 96-well plate with HBVs183-191
peptide at the concentrations indicated for 1.5 h at 37C. T2 cells
loaded with 1 lg/ml HCV NS31073-1081 peptide served as an irrele-
vant peptide (IR) control. T2 cells were washed twice and cocul-
turedwith TCR-ConTor TCR-MAITcells at 37C for 6 h in cRPMI at a
1:1 ratio. HCC cell lines were trypsinised, and 1×105 cells were
seeded into a flat-bottomed 96-well plate. Cells were incubated
overnight at 37C to facilitate adherence and washed twice. TCR-
redirected ConT or MAIT cells were then added to the targets at a
1:1 ratio in their respective medium and cocultured for 24 h.
Flow cytometry
To capture intracellular cytokines, protein transport inhibitors
GolgiPlugTM and GolgiStopTM (final concentration 1:1,000; BD
Biosciences) were added for the final 6 h of coculture assays. The
CD107a antibody, where indicated, was added at the time of T
cell addition to the target cells. HBVs183-91 TCR expression was
quantified by staining with an HLA-A2 dextramer (Immudex)
loaded with FLLTRILTI peptide at 4C for 20 min before surface
antibody staining. To detect endogenous MAIT cell TCR expres-
sion, cells were incubated with either an allophycocyanin (APC)
or phycoerythrin (PE)-labelled 5-(2-oxopropylideneamino)-6-D-
ribitylaminouracil (5-OP-RU)-loaded tetramer (NIH Tetramer
Core Facility) at room temperature (RT) for 40 min before surface
antibody staining. The Near-IR Live/Dead Fixable Dead Cell Stain
Kit (Thermo Fisher) was used to distinguish live cells in all ex-
periments. For extracellular staining, cells were stained for 20
min in FACS buffer (PBS + 2% FCS + 2 mM EDTA). Stained cells
were either fixed in 1× BD CellFix for 10 min at RT or carried
forward for intracellular cytokine staining by fixing in BD Fix/
Perm (BD Biosciences) for 30 min at 4C. Cytokine staining was
performed in 1× Perm/Wash buffer (BD Biosciences) for 30 min.
All antibody stainings were performed at 4C except for those
detecting chemokine receptors, which were performed at RT. All
data were acquired on a BD LSRFortessa instrument and analysed
using FlowJo software (version 10; BD Biosciences).
xCELLigence real-time cytotoxicity assay
The HCC adherent cell lines were tryspinised, and 1×105 cells
were seeded per well of an xCELLigence E-Plate VIEW 16 (Acea
Biosciences). Impedance was monitored at 15-min intervals for
22–24 h using the xCELLigence RTCA DP instrument. For peptide-
pulsed conditions, 1 lg/ml HBVs183-91 peptide (ProImmune) was2vol. 3 j 100318
added to HepG2 cells for 1.5 h before T cell addition and washed
two times in PBS. TCR-redirected ConT or MAIT cells were added
at an effector–target 1:1 ratio and monitored continuously for a
further 48 h. For inflammation conditions, the cells were
cultured in their respective media supplemented with 1,000 IU/
ml IFNc (R&D Systems) and 100 ng/ml TNF (R&D Systems) for the
entire duration of the experiment. Killing was calculated as a
reduction in the AUC of the effector and target conditions rela-
tive to the target only controls for each assay.
3D microfluidic assay and image acquisition
The DAX-1 microdevice (AIM Biotech) was used to perform the
3D coculture of the TCR-redirected T cells with the HepG2-PreS1-
GFP cells as previously described.34–36 Confocal imaging was
performed using a 20× objective (numerical aperture 0.38) on
the Opera Phenix High-Content Screening System (Perkin Elmer)
immediately before and 24 h after addition of the T cells. All
imaging was performed at RT, and the cell culture medium in the
device served as imaging medium. Acquisition was performed
using Perkin Elmer Harmony software. Images were analysed
using Imaris x64 (version 9.6.9; Bitplane).
MAIT cell activation assay
The MAIT cell activation assay was adapted from Dias et al.28 with
minor changes as outlined in the Supplementary information. For
IL-12/IL-18 stimulation, TCR-redirected MAIT cells were incu-
bated in the presence of 10 ng/ml IL-12p70 (PeproTech) and 100
ng/ml IL-18 (MBL) for 24 h. THP-1 killing was defined as 100%
minus the % of live CD3- cells in the forward scatter/side scatter
(FSC/SSC) gate defined in the THP-1 cell-only control. Intracel-
lular cytokines were stained as described above. The MAIT
cell activations were performed in cRPMI supplemented with 50
lg/ml gentamicin (Thermo Fisher) and 100 lg/ml NormocinTM
(InvivoGen) to prevent contamination by non-fixed bacteria.
Statistical analysis
Statistical analysis was performed using Prism software (version
8; GraphPad). Datasets initially underwent normality distribu-
tion testing. The Wilcoxon signed-rank test and paired t tests
were used for paired data. The Friedman test with Dunn’s post
hoc test was performed to detect significance between multiple
paired samples. Two-sided p values <0.05 were considered
significant.
For further details regarding the materials and methods used,
please refer to the Supplementary information and CTAT table.
Results
Generation and characterisation of donor-matched HBV-
specific ConT and MAIT cells
To support the rationale for using blood-derived MAIT cells for
immunotherapy against liver cancer, we analysed the similar-
ities between T cells residing in both tissue compartments using
publicly available single-cell and bulk transcriptome data-
sets.37–39 Conventional CD8+ T cells and MAIT cells derived from
patients with HCC were labelled according to their compart-
ment of origin (matched blood, normal liver tissue, and HCC)
and analysed by Uniform Manifold Approximation and Projec-
tion (UMAP) dimension reduction (Fig. 1A). Unlike the clus-
tering of CD8+ ConT cells, which was highly dependent on the
tissue of origin, a strong co-localisation of MAIT cells was
observed across all tissues, indicating that blood- and liver-JHEP Reports 2021resident MAIT cells share a conserved profile. We reinforced
this shared phenotype using an immunological gene expression
panel on healthy donor-derived T cells as previously
described.39 Analysis of the top 50 upregulated genes in each
cell type relative to their unstimulated controls following
phorbol myristate acetate (PMA)/ionomycin (Fig. S1A) and anti-
CD3/CD28-coupled bead (Fig. S1B) stimulation demonstrated
that MAIT cells from liver and blood share a similar immuno-
logical phenotype following activation. WikiPathway analysis of
the genes in the anti-CD3/CD28 condition supported this piece
of data, with liver MAIT cells sharing 7 pathways with their
blood counterparts, whereas conventional T cells shared 5
pathways (Fig. S1C).
Next, we carried out extensive optimisations of MAIT cell gene
transfer using GFP DNA and mRNA reporters (pVAX-enhanced
GFP) in a total of 56 conditions, eventually selecting a single
condition for the rest of the study (Fig. S2). ConT and MAIT cells
were transfected with HBVs183-91 TCRmRNA (hereafter referred to
as TCR-ConT cells and TCR-MAIT cells, respectively), and surface
expression of the TCR was assessed by flow cytometry using an
HLA-A2 HBVs183-91 dextramer (Fig. 1B). The HBVs183-91 TCR genes
encode a Vb3 TCR chain, which can also be used as a marker of
HBV TCR expression.16 HBV TCR surface expression at 12-h in-
tervals showed similar expression kinetics between the two cell
types, with peak expression 24 h after electroporation. Analysis of
the AUC of HBV TCR expression in MAIT cells also indicated higher
and slightly prolonged TCR expression compared with ConT cells
(Fig. 1C). Post-transfection viability staining showed that ConT
cells were less prone to transfection-associated cell death than
MAIT cells (Fig. 1D). Gating on HBV TCR+ cells did not reveal any
significant differences between ConT and MAIT cells on a CD8+,
CD4+, double-negative, or double-positive level (Fig. 1E). Taken
together, these data demonstrate that blood-derived MAIT cells
represent a readily accessible cell source with a liver-tropic
phenotype distinct to ConT cells. Furthermore, blood-derived
MAIT cells can be engineered with an HBV-specific TCR with
high, but transient efficiency and express a CD8+-enriched
phenotype in line with cytotoxic effector function.
Functional assessment of HBV-specific ConT and MAIT cells
We next compared the specific T cell recognition and activation
profile of HBV TCR-redirected ConT and MAIT cells towards their
new target. First, we performed cocultures with HBVs183-91
(FLLTRILTI) peptide-loaded T2 cells at antigen concentrations
ranging from 10−6 to 103 ng/ml. Given that the ex vivo expanded
MAIT cells have been shown to be CD161 low after expansion,33
and that they downregulate CD161 in response to antigenic
stimulation, we independently assessed MAIT cell purity after
expansion and gated on the total CD3+ populations in both cell
preparations for functional assays (Fig. S3). As shown in Fig. 2A,
TCR-T cell intracellular cytokine staining and SPICE analysis40
after 6 h coculture showed polyfunctional responses down to a
10−2 ng/ml level. Although both T cell types upregulated CD107a
and produced IFNc and TNF in an antigen-specific manner, the
TCR-MAIT cell polyfunctional profile also included elevated
levels of IL-17A. To assess recognition of endogenously processed
HBV in the context of HCC cells, we also performed co-cultures
with HepG2.215 cells, an HCC cell line constitutively expressing
HBV genotype D virus.41 TCR-MAIT cells demonstrated ample
CD107a and TNF responses to the HepG2.215 cells, and the
production of IFNc by TCR-MAIT cells was not statistically
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Fig. 1. Production and flow cytometric analysis of HBV-specific TCR-ConT and TCR-MAIT cells. (A) UMAP dimension reduction plot of blood, normal liver, and
HCC-resident CD8+ and MAIT cell single-cell derived transcriptome datasets. (B) Representative flow cytometry plots from a single donor of HLA-A2-HBVs183-91
dextramer staining in HBVs183-91 TCR mRNA electroporated ConT and MAIT cells 18 h postelectroporation. Mock electroporated T cells served as negative controls.
(C) The HBV TCR expression and (D) cell viability kinetics of transfected ConT and MAIT cells across indicated timepoints and summarized as AUC (n=4 donors). (E)
The percentage of CD8+, CD4+, CD8−CD4−, and CD8+CD4+ cells within the HBV TCR+ ConT and MAIT cell populations (n = 4). The lines and error bars represent the
mean ± standard error of the mean in (C) and (D), and the median ± IQR in (E). A paired t test was performed to detect significance in (C) and (D), and the
Wilcoxon matched-pairs signed-rank test was used to detect significance in (E). *p <0.05, **p <0.01, ***p <0.001. ConT, conventional T; HCC, hepatocellular
carcinoma; HLA, human leukocyte antigen; MAIT, mucosal-associated invariant T cells; n.s., not significant; TCR, T cell receptor; UMAP, Uniform Manifold
Approximation and Projection.
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Fig. 2. Antiviral and cytolytic capacity of HBV TCR-redirected ConT and MAIT cells. (A) Polyfunctional cytokine profile of TCR-ConT and TCR-MAIT cells
following coculture with titrated peptide-loaded T2 cells (n = 1). (B) Representative plots of CD107a, IFNc, TNF, and IL17-A expression after 12-h coculture with
HepG2 cells, HepG2 cells loaded with 1ug/ml HBV peptide, and HepG2.215 cells. (C) Percentages of expression of IFNc, TNFa, and IL-17A by HBV TCR-redirected
ConT and MAIT cells following coculture with the HepG2.2.15 cell line (n = 3 donors). Bars and error bars represent the median and range, respectively. (D)
Normalized cell index curves plotting the adherence of HepG2 cells with and without 1lg/ml HBV peptide during coculture with TCR-ConT and TCR-MAIT cells.
(E) Representative normalized cell index curve of HepG2.2.15 cells only (black), and cocultured with TCR-ConT (blue) or TCR-MAIT (red) cells. The percentage
reduction of the AUC in the presence of TCR-T cells relative to the cell only control is shown. Black dots represent HepG2.215 cells, green dots represent HepG2-
PreS1-GFP cells (n = 4 donors). (F) Fold change of HepG2-PreS1-GFP cell lysis following coculture with TCR-ConT and TCR-MAIT cells in the presence of IFNc and
TNF (inflammation). Fold change was calculated as the AUC of the inflammation conditions relative to the AUC of the respective noninflammation conditions (n =
3 donors). The lines and error bars represent the median ± IQR. The Wilcoxon matched-pairs signed-rank test was used to detect significance. ConT, conventional
T; HCC, hepatocellular carcinoma; IFN, interferon; IR, irrelevant peptide; MAIT, mucosal-associated invariant T cells; n.s., not significant; TCR, T cell receptor; TNF,
tumour necrosis factor.
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Research articleproduction was restricted to the TCR-MAIT cells only, with TCR-
ConT cells remaining IL-17A negative (Fig. 2B,C).
Because the HBVs183-91 TCR has previously demonstrated
anti-HCC functionality,11,16 we next determined how these MAIT
cell responses translated to specific lysis of the target cells. An
impedance-based real-time cytotoxicity assay42 demonstrated
that both cell types were able to effectively lyse FLLTRILTI-loaded
HepG2 cells with antigen specificity confirmed by continued HCC
cell proliferation in the peptide negative control (Fig. 2D). A
similar cytolytic profile was observed in coculture with the HBV
antigen-expressing cell lines HepG2.215 and HepG2-PreS1-GFP.
Plotting the killing efficiency as the change in the AUC relative to
the cell-only controls revealed no significant difference between
the cell types. To determine the impact of inflammation on HBV-
TCR-mediated killing, IFNc and TNF were added to the cultures
as previously described.34 We found that this inflammatory
condition enhanced the killing by both cell types to a similar
extent (Fig. 2F). IFNc is known to upregulate surface expression
of HLA molecules and therefore enhances antigen presentation
to T cells.11 We confirmed this in HepG2.215 cells in Fig. 2G,
where we observed a log-fold increase in HLA-A2 mean fluo-
rescence intensity (MFI) staining after 24 h culture in the
inflammation conditions relative to the unstimulated control
(one representative image of three individual experiments).
These data demonstrate that the induction of functional and
cytotoxic functions in TCR-MAIT cells is rapid, potent, and anti-
gen specific to HBV-associated targets.Chemokine receptor and integrin expression profiles in TCR-
ConT and TCR-MAIT cells
Chemokine receptors and integrins play a crucial role in recruiting
T cells to the liver.43 We have recently noted that MAIT cell ex vivo
expansion enhances their chemokine receptor profile,33 however
whether the TCR engineering protocol influenced their expression
was not known. In line with previous studies, TCR-MAIT cells
expressed high levels of CC chemokine receptor (CCR) 5, CCR6,
and CXC chemokine receptor (CXCR) 6,21 which were little
expressed on TCR-ConT cells (Fig. 3A). Moreover, both cell types
expressed CXCR3, which is associated with tropism towards IFNc-
inducible ligands and antitumoural responses.18 Intermediate
expression levels of CXCR4 and shallow expression of CX3CR1
(<2%) were observed in both TCR-T cells. In addition, constitutive
expression of the integrin very late antigen-4 (VLA-4) was
observed in both cell types, which has been implicated in MAIT
cell residency within the liver biliary epithelium.22
To assess the abundance of ConT and MAIT cells in patients
with HCC, we analysed a publicly available single-cell tran-
scriptome dataset.37–39 We generated UMAP dimension reduc-
tion plots and visualised the cell type and tissue compartment
residency (left panel) together with the tissue distribution of the
selected CCRs as shown in Fig. 3B. As noted, the mean CCR5
expression was low overall, with a broad distribution across the
clusters of interest. By contrast, CCR6 expression was closely
associated with MAIT cells, as well as localisation of normal liver
tissue. High CXCR6 expression was associated with ConT and
MAIT cells residing in normal liver and HCC. CXCR3 clusters
overlapped with CD8+ T cells residing in normal liver and
expression was almost completely overlapping with CD8+ T cells
in all three tissue compartments.
Taken together, these data show that the chemokine receptor
profile of the TCR-MAIT cell is distinct from that of TCR-ConT andJHEP Reports 2021favours tropism towards previously described liver-associated
chemokines.
Enhanced liver tropism of TCR-MAIT cells in a 3D model of the
liver microenvironment
The ability of MAIT cells to migrate and kill HBV antigen
expressing liver targets was investigated in a 3D microfluidic
device, whereby TCR-MAIT and TCR-ConT cells are allowed to
interact with hepatoma cells expressing a GFP reporter cova-
lently linked to the HBV envelope protein (HepG2-PreS1-GFP), as
previously described.34–36 As shown in Fig. 4A, T cells (fluo-
rescently labelled with CellTracker Violet BMQC) loaded in the
proximal fluid channel of the device migrate towards hepatoma
cells embedded in the 3D gel matrix. The inclusion of a viability
dye (DRAQ7) facilitates the quantification of dead target cells at
0 and 24 h after T cell addition. The image analysis pipelines for
calculating the T cell migration and dead cell indices are shown
in Fig. S4. Cocultures were performed under hypoxic and nor-
moxic conditions to simulate the HCC hypoxic microenviron-
ment. Compared with TCR-ConT, the TCR-MAIT from all three
donors migrated significantly more efficiently in both hypoxic
(2%) and normoxic (20%) O2 concentrations towards the target
hepatoma cells, and in the presence of inflammation, this was
observed in 1 other donor (Fig. 4B). In 2 of 3 donors (donors 1
and 2), the killing capacity of TCR-MAIT cells appeared similar or
higher than that of TCR-ConT cells in both normoxic and hypoxic
conditions and also in the presence of inflammation. Conversely,
donor 3 TCR-ConT cells outperformed TCR-MAIT cells in these
conditions (Fig. 4C). In conclusion, under most conditions, the
TCR-MAIT cells migrated more readily towards the hepatoma
tumour target, which is in line with their chemokine receptor
profile.TCR-MAIT cells retain their ability to respond to Escherichia
coli-fed THP-1 cells and IL-12/IL-18 activation
The functional responses of TCR-MAIT cells through the intro-
duced HBV TCR raised the question of whether they are still
capable of exerting their innate-like functions. Co-expression of
two TCRs was confirmed by simultaneously staining with a 5-OP-
RU-loaded MR1 tetramer and the HBV TCR-specific antibody 24 h
after electroporation. As shown in Fig. 5A, the expression of the
HBV TCR had a minor impact on the 5-OP-RU-loaded MR1
tetramer binding of TCR-MAIT cells; the vast majority had
detectable signal albeit with reduced staining intensity (Fig. 5B).
Next, the quality of MR1-dependent or MR1-independent re-
sponses were examined by testing TCR-MAIT cells in a THP-1 cell
model loaded with E. coli (Fig. 5C). TCR-MAIT cells efficiently
killed E. coli pulsed THP-1 cells relative to controls without
bacteria, an effect that was partially dependent on MR1 (blocked
by MR1 Ab). Following THP-1 + E. coli stimulation, TCR-MAIT cells
upregulated CD107a, as well as the proinflammatory cytokines
IFNc, TNF, and IL-17A (Fig. 5D,E). Anti-MR1 blockade further
confirmed that CD107a degranulation and cytokine responses
were dependent on MR1 as no statistically significant differences
were observed between the THP-1 control and the MR1-
blockade condition. Furthermore, Fig. 5F,G shows that TCR-
MAIT cells were activated by IL-12/IL-18 stimulation, resulting
in the production of IFNc. The latter is attributed to the previ-
ously described mechanism by which MAIT cells play a role in
antiviral immunity.44 These data demonstrate that MAIT cell
innate-like functions are well-preserved after TCR redirection6vol. 3 j 100318
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Fig. 3. Chemokine receptor, integrin, and activation profile of donor-matched TCR-ConT and MAIT cells. (A) Representative flow cytometry histograms and
summary plots of CCR5, CCR6, CXCR3, CXCR4, and CXCR6, CX3CR1, and VLA-4 expression in donor-matched TCR-T cells (n = 3 donors). The FMO controls are
shown as black dashed lines. (B) UMAP dimension reduction plots of Leiden clustering by cell type and tissue compartment (left panel). The mean expression of
the chemokine receptor transcripts of interest was also plotted using the same community detection algorithm (right panel). The lines and error bars represent
the median ± IQR in (A). CCR, CC chemokine receptor; ConT, conventional T; CXCR, CXC chemokine receptor; FMO, fluorescence minus one; HCC, hepatocellular
carcinoma; MAIT, mucosal-associated invariant T cells; TCR, T cell receptor; UMAP, Uniform Manifold Approximation and Projection; VLA-4, very late antigen 4.and they can recognise multiple antigenic targets through their
dual TCR expression.Discussion
In this study, we show that ex vivo expanded MAIT cells can be
redirected towards recognition of HBV antigens through theJHEP Reports 2021transfer of virus-specific TCR mRNA. Although MAIT cells are
known to exert cytolytic and antiviral effector functions, previ-
ous studies have highlighted these properties in the context of
innate-like responses during microbial infection. Here, we
demonstrated a methodology that can render MAIT cells specific
to the vast antigenic potential of MHC class I-restricted targets.
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Fig. 4. TCR-T cell migration and hepatoma cell killing in a 3D microfluidic device. (A) Representative maximum intensity projection images of HepG2-PreS1-
GFP cells (green) in the presence of a DRAQ7 dead cell marker (red) before and after 24 h coculture with TCR-ConT and TCR-MAIT cells. The T cells (blue) were also
labelled with a violet cell tracker to quantify their migration towards the hepatoma cells. (B) The migratory properties of the TCR-T cells under different conditions
recapitulating the HCC microenvironment was investigated (normoxic and hypoxic cocultures with and without inflammatory cytokines). Collagen gel infiltration
is presented as the T cell migration index (the number of T cells that migrate into the device after 24 h coculture normalized to the number of HepG2-preS1 cells
within the gel at the time of T cell injection). (C) The killing of HBV Pre-S1-expressing target cells by the TCR-T cells. The TCR normalized DCI was calculated by
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=
controlling for differences in TCR transfection efficiency as described. All experiments were performed using 3 healthy donors, and each condition was performed
in triplicate. The scale bare represents 100 lm. The lines and error bars represent the median ± IQR. The Wilcoxon matched-pairs signed-rank test was used to
detect significance between paired samples. *p <0.05, **p <0.01, ***p <0.001. ConT, conventional T; DCI, dead cell index; HCC, hepatocellular carcinoma; MAIT,
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Fig. 5. HBV TCR-MAIT cells retain their ability to be activated by MR1-restricted targets and IL-12/IL-18 stimulation. The effect of HBV TCR expression on the
percentage (A) and MFI (B) of 5-OP-RU loaded MR1 tetramer binding. (C) Summary plot of THP-1 killing by TCR-MAIT cells following 24 h coculture with non-
loaded and E. coli-fed THP-1 cells. An MR1 blocking antibody was used in parallel to investigate MR1 dependency on killing. Representative flow cytometry
histograms (D) and summary plot (E) of CD107a, IFNc, TNF, and IL-17A expression under the same conditions. (F) Representative and (G) combined donor data of
IFNc MFI in TCR-MAIT cells with and without stimulation with IL-12/IL-18. The experiment was performed on 4 donors. The lines and error bars represent the
median ± IQR in (A), (C), and (E), and the mean ± standard error of the mean in (B) and (G). To detect significance between paired samples, the Wilcoxon matched-
pairs signed-rank test was used in (A), and a paired t test was performed in (B) and (G). The Friedman test with Dunn’s post hoc test was performed to detect
significant differences between multiple paired samples in (C) and (E). *p <0.05, **p <0.01, ***p <0.001. 5-OP-RU, 5-(2-oxopropylideneamino)-6-D-ribitylami-
nouracil; IFN, interferon; MAIT, mucosal-associated invariant T; MFI, mean fluorescence intensity; MR1, major histocompatibility complex class I-related
molecule; n.s., not significant; TCR, T cell receptor; TNF, tumour necrosis factor.
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Research articleprofile, can be exploited as a therapeutic alternative to ConT cells,
which are currently used in immunotherapy. Furthermore, this
approach has strong translational potential, as we have recently
shown that this method is capable of producing therapeutically
relevant numbers of functional MAIT cells for transduction and
subsequent transfer (up to 1.9×109 MAIT cells from 50 ml of buffy
coat).33
Initially, we demonstrated that MAIT cells engineered towards
alternative MHC class I-restricted specificities are highly func-
tional, with an array of robust effector functions applicable to
HBV immunotherapy. These included polyfunctional cytokine
responses, and rapid, potent cytotoxicity, which is in-line with
what is known about their effector phenotype.45 One dis-
tinguishing feature of TCR-MAIT cells was the production of IL-
17A upon encountering HBV antigens. MAIT cells are the pri-
mary IL-17-producing cell type in the liver,23 so this observation
was not surprising, although it did constitute a function not seen
in ConT cells. The role of IL-17-producing T cells in tumour im-
munity, however, is still controversial46; in mouse models,
blocking IL-1747 and adoptive transfer of tumour-specific IL-17-
producing CD8+ T cells48 have both demonstrated antitumoural
effects. It has been proposed that the tumour-specific niche
within which the IL-17-producing cell resides determines
whether IL-17 will be protumorigenic or antitumorigenic.46
Therefore, local tumour microenvironment factors, including
inflammation status and immune cell composition, could be
important for the pathological outcome.
Another difference in the functional profile of both cell types
was the differential expression of IFNc in the TCR-ConT and
TCR-MAIT cells following coculture with the HepG2.215 cell
line. It is important to note that MAIT cells from the same donor
and expansion culture were used for the HBV-associated func-
tional assays as in the E. coli and IL-12/IL-18 studies shown later
in the manuscript. In the latter, we demonstrated that TCR-
MAIT cells were capable of producing large amounts of IFNc
in response to their natural innate targets, confirming that their
IFNc-secreting properties were intact after expansion and
redirection. However, when activated by the acquired HLA-
restricted TCR, their IFNc response appeared to be under the
influence of the antigen source and peptide magnitude. Indeed,
the differential expression of IFNc by TCR-ConT and IL-17A by
TCR-MAIT cells is a feature that may have relevance depending
on the downstream applications of the cell product. For
example, adoptive transfer of a T cell type that induces a potent
proinflammatory response, such as IL-17, may be beneficial
from the perspective of tumour elimination, whereas IFNc
production in response to HBV antigens may be more advan-
tageous in the context of viral control. Further investigation of
the cytokine profile of TCR-MAIT cells upon encountering low-
density targets and following redirection with low-affinity
TCRs are also warranted.
In addition to functional and cytotoxic potential, MAIT cell
tropism towards the liver formed the basis for their selection for
HBV-HCC immunotherapy. We have recently observed that our
MAIT cell expansion protocol significantly alters their chemokine
receptor profile, driving them towards a unique tissue-homing
phenotype.33 In line with that study, the TCR-engineered MAIT
cells expressed high levels of CCR5, CCR6, CXCR3, CXCR6, and the
integrin VLA-4. The recruitment of MAIT cells from the blood has
been shown to be associated with the expression of CXCR3 and
VLA-4.22 In addition to providing physical adhesive support, the
binding of VLA-4 to its ligand, VCAM-1, can also support T cellJHEP Reports 2021persistence by inhibiting T cell apoptotic signalling.49 CXC che-
mokine ligand (CXCL) 9, CXCL10, and CXCL11 can all be induced
by IFNc, and therefore, an influx of cells that produce IFNc in
response to activation may be of benefit for augmenting T cell
migration through the CXCR3 axis.50 The tumorigenic process is
also known to alter the chemokine production profile of HCC,
and screening of the chemokine receptor profile of the cell
product, in combination with expression of their cognate ligands
within the target tumour, could predict the efficacy of the ther-
apy. To provide more insight into which combinations of che-
mokine receptors may enhance MAIT cell migration towards
HepG2, systematic blocking experiments will be required in
future studies.
The 3D microfluidics system used in this study represents a
more practical and rigorous evaluation of the TCR-T cells as they
also need to actively migrate towards the tumour targets, an
interaction that cannot be recapitulated in classical gravity-
driven 2D coculture assays.34 Under most conditions, we
demonstrated that TCR-MAIT cells migrated more readily to-
wards the hepatocytes than did TCR-ConT cells, which aligns
with the chemokine receptor phenotype we presented. Inter-
estingly, MAIT cell migration towards the HCC cells was inde-
pendent of the HBV-TCR expression, with mock-transfected
MAIT cells infiltrating the gel region with comparable efficiency
(data not shown). Although the 2D culture experiments
demonstrated consistent functionality between donors, inter-
donor variation was mainly observed in the 3D cocultures.
Several different factors may contribute to this variation: che-
mokine receptor density, hypoxia-inducible factors, and differing
immunometabolic status between donors can all modulate the
intensity of the stimulus, thereby affecting the magnitude of the
downstream signalling pathways. Taken together, the differences
observed between donors highlights the sensitivity of this assay,
as well as the importance of preclinical testing for predicting the
success of an immunotherapy for a specific patient.
We found that the ectopic TCR expression did not prevent
TCR-MAIT cells from exerting their intrinsic innate-like proper-
ties, indicating that they still support defence against invading
pathogens such as E. coli. Recent studies indicate that solid tu-
mours are often enriched with intracellular bacteria51 and that
these intratumoural microbiota can interfere with cancer ther-
apy.52 Furthermore, a leaky gut in patients with liver disease can
drive MAIT cell dysfunction and bacterial infection susceptibil-
ity.53 Increased bacterial loads and coinfection of patients
already critically ill with chronic viral infection can drive tumour
progression. Therefore, the administration of a T cell therapy
targeting multiple facets of the tumorigenic process may be of
clinical benefit. The various aspects of these functions, for
example, responsiveness towards microbiota and stimulation
through MR1, remain to be systematically explored in new
studies to assess whether they might increase the efficiency of
TCR-MAIT cells in killing HepG2 in an antigen-specific manner.
MAIT TCR-dependent and MAIT TCR-independent signalling are
known to work synergistically during MAIT cell activation,45
and whether this effect also occurs in the context of dual TCR
expression deserves to be explored. The ability of MAIT cells to
be activated by cytokines independently of their TCR is also
interesting. Although they may be able to boost TCR-dependent
responses, the unpredictability of non-specific activation in
off-target sites should be considered prior to clinical translation.
MAIT cell therapy could be potentially used as an adjuvant or
alternative to other available therapies against advanced10vol. 3 j 100318
HCC or recurrent HCC, such as immune checkpoint inhibition.
This is of significance in patients with resistance to immune
checkpoint inhibitor therapy, which has poor prognostic
outcomes.
However, this study has some limitations. Although this T cell
immunotherapy was being investigated in the context of HBV-
HCC, all functional experiments were performed using healthy
donor PBMCs. Given that MAIT cell functionality during chronic
HBV infection54 and HCC37 is altered, the functional responses
observed in this study may not be reflective of patient cell per-
formance. Moreover, the lack of clinical data relating to MAIT cell
adoptive transfer means that it is difficult to predict how safe and
well tolerated this therapy would be in vivo. For example, po-
tential formation of mixed TCR dimers is one safety concern that
should be screened by co-staining with MAIT cell TCRa and HBVJHEP Reports 2021TCRb chains in future translational studies. Because the ectopic
TCR originally comes from another donor, alloreactivity may also
occur. However, the lack of available animal models for HBV-HCC
means that rigorous preclinical evaluation is limited. Although
studying T cell–tumour cell interactions in a 3D system offers
important insights into T cell migratory and functional proper-
ties, HCC is a complex tumour to model in vitro. Our study did
not address fibrotic tissue or MAIT cell interactions with local
immune cells, which are important considerations for liver
immunotherapy.
Overall, this study provides important novel insights into the
potential of human MAIT cells for targeting HCC. However,
future studies with patient-derived MAIT cells, as well as the
range of non-HBVmicrobial factors that they can respond to, are
required.Abbreviations
5-OP-RU, 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil; APC, allo-
phycocyanin; CAR, chimeric antigen receptor; CCR, CC chemokine re-
ceptor; ConT, conventional T; CXCL, chemokine (CXC) ligand; CXCR, CXC
chemokine receptor; DCI, dead cell index; FMO, fluorescence minus one;
FSC, forward scatter; HCC, hepatocellular carcinoma; HLA, human
leukocyte antigen; IFN, interferon; IR, irrelevant peptide; MAIT, mucosal-
associated invariant T; MFI, mean fluorescence intensity; MHC, major
histocompatibility complex; MR1, MHC class I-related molecule; PBMC,
peripheral blood mononuclear cell; PE, phycoerythrin; PMA, phorbol
myristate acetate; RT, room temperature; SSC, side scatter; TCR, T cell
receptor; TNF, tumour necrosis function; UMAP, Uniform Manifold
Approximation and Projection; VCAM-1, vascular cell adhesion molecule-
1; VLA-4, very late antigen-4.
Financial support
This studywas supported bygrants toMSC from the Swedish Cancer Society
(CAN2016/731, 19 0495 Pj 01 H) and Karolinska Institutet funding for
doctoral students (KID-funding). Additional funds were provided by a KI –
Johnson & Johnson Innovation/Janssen grant to J.K.S., M.S.C., and A.B.. K.H.
received funding from the Erik and Edith Fernström Foundation for Medical
Research, Sweden. A.P. is supported by the Singapore Ministry of Health’s
National Medical Research Council under the Open Fund – Young Investi-
gator Grant (OF-YIRG MOH-OFIRG18nov-0007). S.E.R. is financially sup-
ported by the Knut and AliceWallenberg Foundation as part of the National
Bioinformatics Infrastructure Sweden at SciLifeLab. Further funding to J.K.S.
was from the Swedish Research Council (2016-03052) and the Swedish
Cancer Society (CAN 2017/777). A.B. is supported by the Singapore Ministry
of Health’s National Medical Research Council under its Singapore Trans-
lational Research Investigator Award (NMRC/STaR/0013/2012).
Conflicts of interest
A.P. is a shareholder and consultant for AIM Biotech Pte Ltd. A.B. and A.T.T.
are the Scientific Founder and the Scientific Consultant of Lion TCR Pte.
Ltd., respectively, a biotech company developing T cell receptors for
treatment of virus-related diseases and cancers. The other authors
declare no conflicts of interest that pertain to this work. Please refer to
the accompanying ICMJE disclosure forms for further details.
Authors’ contributions
Conceived the study design: M.S.C., K.H., J.K.S., A.B. Planned and per-
formed the experiments: K.H., A.P., T.P., M.J.S., A.T.T. Analysed and inter-
preted the data: K.H., A.P., T.P., S.E.R., H.D., A.T.T., MSC. Contributed clinical
material and data interpretation: S.A. Supervised the work: M.S.C., A.B.,
J.K.S., A.P. Wrote the manuscript: K.H., M.S.C. Reviewed and revised the
manuscript critically: all authors.
Data availability statement
Data supporting this study will be made available upon reasonable
request to the corresponding author.Acknowledgements
The authors would like to thank Joey Aw and Damien Tan for technical
assistance during the project. The MR1 tetramer was developed by Dr.
James McCluskey, Dr. Jamie Rossjohn, and Dr. David Fairlie, and the
material was produced by the NIH Tetramer Core Facility (distributed by
the University of Melbourne). The graphical abstract figure was created
using BioRender. The 3D imaging analysis was performed at the LCI
facility/Nikon Center of Excellence, Karolinska Institutet, supported by
grants from the Knut and Alice Wallenberg Foundation, Swedish
Research Council, KI infrastructure, Centre for Innovative Medicine, and
The Jonasson Center at the Royal Institute of Technology. The authors
would also like to thank Dr. Ian Strickland for proofreading the
manuscript.
Supplementary data
Supplementary data to this article can be found online at https://doi.org/1
0.1016/j.jhepr.2021.100318.
References
Author names in bold designate shared co-first authorship
[1] Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al.
The burden of primary liver cancer and underlying etiologies from 1990 to
2015 at the global, regional, and national level: results from the global
burden of disease study 2015. JAMA Oncol 2017;3:1683–1691.
[2] Balogh J, Victor 3rd D, Asham EH, Burroughs SG, Boktour M, Saharia A,
et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma
2016;3:41–53.
[3] Raza A, Sood GK. Hepatocellular carcinoma review: current treatment,
and evidence-based medicine. World J Gastroenterol 2014;20:4115–4127.
[4] El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al.
Nivolumab in patients with advanced hepatocellular carcinoma (Check-
Mate 040): an open-label, non-comparative, phase 1/2 dose escalation
and expansion trial. Lancet 2017;389:2492–2502.
[5] Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pem-
brolizumab in patients with advanced hepatocellular carcinoma previ-
ously treated with sorafenib (KEYNOTE-224): a non-randomised, open-
label phase 2 trial. Lancet Oncol 2018;19:940–952.
[6] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy:
from T cell basic science to clinical practice. Nat Rev Immunol
2020;20:651–668.
[7] Bertoletti A, Tan AT. Challenges of CAR- and TCR-T cell-based therapy for
chronic infections. J Exp Med 2020;217:e20191663.
[8] Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR,
Weissinger EM, et al. Adoptive transfer of pp65-specific T cells for the
treatment of chemorefractory cytomegalovirus disease or reactivation
after haploidentical and matched unrelated stem cell transplantation.
Blood 2010;116:4360–4367.
[9] Tang K-W, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The
landscape of viral expression and host gene fusion and adaptation in
human cancer. Nat Comm 2013;4:2513.11vol. 3 j 100318
Research article[10] Sung W-K, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of
recurrent HBV integration in hepatocellular carcinoma. Nat Genet
2012;44:765–769.
[11] Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, et al. Use of
expression profiles of HBV-DNA integrated into genomes of hepatocellular
carcinoma cells to select T cells for immunotherapy. Gastroenterology
2019;156. 1862–1876.e1869.
[12] Gehring AJ, Xue S-A, Ho ZZ, Teoh D, Ruedl C, Chia A, et al. Engineering
virus-specific T cells that target HBV infected hepatocytes and hepato-
cellular carcinoma cell lines. J Hepatol 2011;55:103–110.
[13] Bohne F, Chmielewski M, Ebert G, Wiegmann K, Kürschner T, Schulze A,
et al. T cells redirected against hepatitis B virus surface proteins eliminate
infected hepatocytes. Gastroenterology 2008;134:239–247.
[14] Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, Lütgehetmann M, et al.
Lymphocytes transiently expressing virus-specific T cell receptors reduce
hepatitis B virus infection. J Clin Invest 2017;127:3177–3188.
[15] Krebs K, Böttinger N, Huang L-R, Chmielewski M, Arzberger S,
Gasteiger G, et al. T cells expressing a chimeric antigen receptor that binds
hepatitis B virus envelope proteins control virus replication in mice.
Gastroenterology 2013;145:456–465.
[16] Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, et al. A practical
approach to immunotherapy of hepatocellular carcinoma using T cells
redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013;2:e114.
[17] Qasim W, Brunetto M, Gehring AJ, Xue S-A, Schurich A, Khakpoor A, et al.
Immunotherapy of HCC metastases with autologous T cell receptor
redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol
2015;62:486–491.
[18] Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors.
Cancer Res 2014;74:7168–7174.
[19] Martinez M, Moon EK. CAR T Cells for solid tumors: new strategies for
finding, infiltrating, and surviving in the tumor microenvironment. Front
Immunol 2019;10:128.
[20] Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J, et al.
Expression of a functional CCR2 receptor enhances tumor localization and
tumor eradication by retargeted human T cells expressing a mesothelin-
specific chimeric antibody receptor. Clin Cancer Res 2011;17:4719–4730.
[21] Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D, et al.
Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-
17–secreting T cells. Blood 2011;117:1250–1259.
[22] Jeffery HC, van Wilgenburg B, Kurioka A, Parekh K, Stirling K, Roberts S,
et al. Biliary epithelium and liver B cells exposed to bacteria activate
intrahepatic MAIT cells through MR1. J Hepatol 2016;64:1118–1127.
[23] Kurioka A, Walker LJ, Klenerman P, Willberg CB. MAIT cells: new guard-
ians of the liver. Clin Transl Immunol 2016;5:e98.
[24] van Wilgenburg B, Loh L, Chen Z, Pediongco TJ, Wang H, Shi M, et al. MAIT
cells contribute to protection against lethal influenza infection in vivo.
Nat Commun 2018;9:4706.
[25] Wong EB, Ndung’u T, Kasprowicz VO. The role of mucosal-associated
invariant T cells in infectious diseases. Immunology 2017;150:45–54.
[26] Crowther MD, Dolton G, Legut M, Caillaud ME, Lloyd A, Attaf M, et al.
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer
targeting via the monomorphic MHC class I-related protein MR1. Nat
Immunol 2020;21:178–185.
[27] Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, et al.
MAIT cells are licensed through granzyme exchange to kill bacterially
sensitized targets. Mucosal Immunol 2015;8:429–440.
[28] Dias J, Sobkowiak MJ, Sandberg JK, Leeansyah E. Human MAIT-cell re-
sponses to Escherichia coli: activation, cytokine production, proliferation,
and cytotoxicity. J Leukoc Biol 2016;100:233–240.
[29] Dias J, Boulouis C, Sobkowiak MJ, Lal KG, Emgård J, Buggert M, et al.
Factors influencing functional heterogeneity in human mucosa-
associated invariant T cells. Front Immunol 2018;9:1602.
[30] Rha M-S, Han JW, Kim JH, Koh J-Y, Park HJ, Kim SI, et al. Human liver CD8+
MAIT cells exert TCR/MR1-independent innate-like cytotoxicity in
response to IL-15. J Hepatol 2020;73. 64–50.
[31] Godfrey DI, Le Nours J, Andrews DM, Uldrich AP, Rossjohn J. Unconven-
tional T cell targets for cancer immunotherapy. Immunity 2018;48:453–
473.
[32] Healy K, Pasetto A, Sobkowiak MJ, Soon CF, Cornberg M, Aleman S, et al.
Chronic viral liver diseases: approaching the liver using T cell receptor-
mediated gene technologies. Cells 2020;9:1471.JHEP Reports 2021[33] Parrot T, Healy K, Boulouis C, Sobkowiak MJ, Leeansyah E, Aleman S, et al.
Expansion of donor-unrestricted MAIT cells with enhanced cytolytic
function suitable for TCR-redirection. JCI Insight 2021;6:e140074.
[34] Pavesi A, Tan AT, Koh S, Chia A, Colombo M, Antonecchia E, et al. A 3D
microfluidic model for preclinical evaluation of TCR-engineered T cells
against solid tumors. JCI Insight 2017;2:e89762.
[35] Preece R, Pavesi A, Gkazi SA, Stegmann KA, Georgiadis C, Tan ZM, et al.
CRISPR-mediated base conversion allows discriminatory depletion of
endogenous T Cell Receptors for Enhanced Synthetic Immunity. Mol Ther
Methods Clin Dev 2020;19:149–161.
[36] Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, et al.
Molecular recalibration of PD-1+ antigen-specific T cells from blood and
liver. Mol Ther 2018;26:2553–2566.
[37] Yao T, Shooshtari P, Haeryfar SMM. Leveraging public single-cell
and bulk transcriptomic datasets to delineate MAIT cell roles and
phenotypic characteristics in human malignancies. Front Immunol
2020;11:1691.
[38] Zheng C, Zheng L, Yoo J-K, Guo H, Zhang Y, Guo X, et al. Landscape of
infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell
2017;169. 1342–1356.e1316.
[39] Tang X-Z, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et al. IL-7 licenses
activation of human liver intrasinusoidal mucosal-associated invariant T
cells. J Immunol 2013;190:3142–3152.
[40] Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of
post-cytometric complex multivariate datasets. Cytometry A
2011;79:167–174.
[41] Acs G, Sells MA, Purcell RH, Price P, Engle R, Shapiro M, et al. Hepatitis B
virus produced by transfected Hep G2 cells causes hepatitis in chim-
panzees. Proc Natl Acad Sci U S A 1987;84:4641–4644.
[42] Peper JK, Schuster H, Löffler MW, Schmid-Horch B, Rammensee H-G,
Stevanovic S. An impedance-based cytotoxicity assay for real-time and
label-free assessment of T-cell-mediated killing of adherent cells.
J Immunol Methods 2014;405:192–198.
[43] Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of
lymphocytes to the liver. Dig Dis 2010;28:31–44.
[44] Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, et al.
CD161++CD8+ T cells, including the MAIT cell subset, are specifically
activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol
2014;44:195–203.
[45] Hinks TSC, Zhang X-W. MAIT cell activation and functions. Front Immunol
2020;11:1014.
[46] Kuen D-S, Kim B-S, Chung Y. IL-17-producing cells in tumor immunity:
friends or foes? Immune Netw 2020;20:e6.
[47] Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, et al. Redundant innate
and adaptive sources of IL17 production drive colon tumorigenesis. Can-
cer Res 2016;76:2115–2124.
[48] Yu Y, Cho H-I, Wang D, Kaosaard K, Anasetti C, Celis E, et al. Adoptive
transfer of Tc1 or Tc17 cells elicits antitumor immunity against estab-
lished melanoma through distinct mechanisms. J Immunol
2013;190:1873–1881.
[49] Afford SC, Humphreys EH, Reid DT, Russell CL, Banz VM, Oo Y, et al.
Vascular cell adhesion molecule 1 expression by biliary epithelium pro-
motes persistence of inflammation by inhibiting effector T-cell apoptosis.
Hepatology 2014;59:1932–1943.
[50] Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and
antagonistic functions. Immunol Cell Biol 2011;89:207–215.
[51] Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, et al. The
human tumor microbiome is composed of tumor type-specific intracel-
lular bacteria. Science 2020;368:973–980.
[52] Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D,
et al. Potential role of intratumor bacteria in mediating tumor resistance
to the chemotherapeutic drug gemcitabine. Science 2017;357:1156–1160.
[53] Riva A, Patel V, Kurioka A, Jeffery HC, Wright G, Tarff S, et al. Muco-
sa-associated invariant T cells link intestinal immunity with
antibacterial immune defects in alcoholic liver disease. Gut 2018;67:918–
930.
[54] Boeijen LL, Montanari NR, de Groen RA, van Oord GW, van der Heide-
Mulder M, de Knegt RJ, et al. Mucosal-associated invariant T cells are
more activated in chronic hepatitis B, but not depleted in blood: reversal
by antiviral therapy. J Infect Dis 2017;216:969–976.12vol. 3 j 100318
